Compare Palantir Technologies Inc (PLTR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs BIO-TECHNE Corp — how do they compare? Palantir Technologies Inc trades at $209.05 (market cap $477.68B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Palantir Technologies Inc is far larger — about 42× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and BIO-TECHNE Corp for 64 Days on average.
| PLTR | TECH | |
|---|---|---|
Market Cap | $477.68B | $11.36B |
Volume | 41,744,992 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $209.05 | $72.61 |
52-Week Low | $107.27 | $43.31 |
Typical Hold Time | 78 Days | 64 Days |
Enterprise Value | $468.48B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $198.78, up 2.44% today, approaching its 52-week high with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Recent technical indicators show overbought conditions with RSI above 76, while analyst consensus remains positive with 54% buy ratings and $191.69 price target. The company's partnership with Armada for sovereign AI infrastructure represents significant growth catalyst.
PLTR presents compelling growth prospects driven by AI platform adoption and expanding commercial customer base, though premium valuations (P/E 169.9, P/S 83.02) require sustained execution. Key risks include growth rate normalization and competitive pressures in AI software. Current momentum suggests potential for continued upside if earnings beat streak continues through Q3 2026.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
